|
|
 |
|
Viewing report
|
|
|
|
Cancer, CNS & Cardiovascular Biomarkers: Players, Products and Prospects
Espicom Business Intelligence Ltd, Aug 2008, Pages: 352
By 2015, the biomarker market is forecast to be worth over US$20 billion as the cardiovascular and CNS biomarker market segments begin to mature with the launch of a number of diagnostic tests to guide the treatment of neuropsychiatric and neurodegenerative diseases.
This new 3-volume report provides a comprehensive analysis of the major therapy areas which are driving growth, along with a critical assessment of the companies involved.
Unique analysis and scoring
To provide commercial and industry managers with qualified insight to the corporate landscape, the report provides a unique assessment and scoring system for each company covering:
- Biomarker technology
- Association/clinical studies
- Management strategy
- Application & potential
Over 350 information-packed pages providing:
-- Forecasts of biomarker market value and therapy share to 2015
-- Detailed analysis of the products and potential of:
- 40 Cancer
- 29 CNS
- 34 Cardiovascular companies active in each sector
Major biomarker approaches include:
- Proteomics
- RNA & MicroRNA
- DNA
- Metabolic
- Electrophysiology
Also available
Cancer Biomarkers: Players, Products and Prospects (Volume I)
Cancer Biomarkers: Players, Products and Prospects (Volume I)
CNS Biomarkers: Players, Products and Prospects (Volume II)
CNS Biomarkers: Players, Products and Prospects (Volume II)
Cardiovascular Biomarkers: Players, Products and Prospects (Volume III)
Customers who bought this item also bought
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Blood Biomarkers and Beyond: Biomarker and Diagnostic Opportunities in Cardiovascular Disease
Licensing Strategies for Accessing Biomarker Technologies
Cardiovascular Biomarkers: Players, Products and Prospects (Volume III)
Biomarker and Diagnostic Opportunities in Clinical Research for Neurological Diseases
It's All About the Biomarkers: How 2008's Biomarker-Based Partnering Is Driving Personalized Medicine
CNS Biomarkers: Players, Products and Prospects (Volume II)
Clinical Proteomics: Rethinking Approaches to Protein Biomarker Discovery
Cancer Biomarkers: Players, Products and Prospects (Volume I)
How Overcoming the Challenge of Biomarker Validation Can Pay Off for Drug and Diagnostic Developers
Harnessing Biomarker Research in Academic Institutions for Use in Industry
Uncovering Biomarker and Diagnostic Opportunities in Immune and Inflammatory Diseases
|
|
|
|
